Staff Profile
Career Summary
Biography
For more than 15 years, Dr Xu Dong Zhang has focused on translational melanoma research with an overall aim to overcome resistance of metastatic melanoma to treatment. He is currently a Professor heading the Melanoma Research Laboratory (Oncology and Immunology Unit) of the University of Newcastle (UoN)/Calvary Mater Newcastle Hospital (CMN) that consists of 3 postdoctoral researchers, 2 research assistants, 2 visiting academics, 6 PhD students, 1 laboratory manager, 1 technical officer, and 1 administrative officer. Professor Zhang has published more than 80 manuscripts in his research career. The H Factor (Index) of his publications is currently 26. In addition, He has presented my work in a large number of international and national conferences and institutional seminars, with many attendances as an invited speaker. As a chief investigator, He has attracted a large sum of funding for his research. In the past 3 years since, he was awarded an NHMRC Senior Research Fellowship (2011), and successfully renewed, for the third consecutive time, a Cancer Institute NSW (CINSW) Fellowship (2011) that is now awarded in the form of a top-up to the NHMRC Fellowship. He is a chief investigator of a translational melanoma research program grant awarded in 2011 by CINSW, and, as Chief investigator A, he has received 2 NHMRC project grants and 2 Cancer Council NSW project grants since 2009. In addition, He is a co-chief investigator of another NHMRC project grant and a chief investigator of a number of competitive grants from other funding bodies. Professor Zhang’s research has drawn considerable attention in the cancer research community worldwide and his contribution to melanoma research is highly regarded nationally and internationally. He regularly review manuscripts for high impact journals including Cancer Research and Oncogene, and assess grant applications for international and national funding bodies, such as Medical Research Council UK and NHMRC. He was a Grant Review Panel (GRP) member of NHMRC in 2011. His research has also drawn extensive attention from the general public, with the highlight being 4 interviews by media including the ABC in the past 3 years. His research excellence has enabled me to establish productive collaborations with other researchers, both within academia and commercial organizations. In addition, I provide regular scientific consultancies not only locally and nationally, but also to cancer researchers of a number of highly ranked universities and institutes in China. He has proven himself to be highly competent in supervision of research high degree students and junior researchers. Since he received my first conjoint appointment in 2005 from the University of Newcastle, two PhD students have completed their studies in excellent fashion under my supervision. During the past 3 years, two postdoctoral researchers have successfully obtained NHMRC Postdoctoral Training Fellowship under his supervision. At the current time, he is the principal supervisor of 5 PhD candidates, and a co-supervisor of another two. Professor Zhang is a Co-Director of the Priority Research Centre (PRC) for Cancer of the Faulty of Health, and a Deputy Director of the Cancer Program of Hunter Medical Research Institute. He is also a member of various scientific and administering committees, including the HMRI Research Council, the Research Council of Hunter Translational Cancer Research Unit, and the Analytical and Biomolecular Research Facility Advisory Group of University of Newcastle.
Qualifications
- PhD, University of Sydney, 04/05/2002
- Bachelor of Medicine, Shanxi Medical University PR China, 31/08/1986
Research
Research keywords
- Carcinogenesis
- Cell Death
- Oncology
- Signal Transduction
Research expertise
Melanoma is the most serious form of skin cancer that is often referred to as Australia's national cancer as Australia has the highest incidence of melanoma in the world. However, there is currently no curative treatment once the disease spreads beyond the original site. To address this major Australian health problem, Professor Xu Dong Zhang has been working on translational research on melanoma with a focused theme of “overcoming resistance of metastatic melanoma to treatment” for more than 15 years. In particular, he has been recognized nationally and internationally for his significant contribution to understanding resistance mecahnisms of melanoma cells to apoptosis, a form of cell death that is the main mechanism of killing of cancer cells by most anti-cancer therapeutic drugs.
Professor Zhang is currently leading the Melanoma Research Laboraotory (Oncology and Immunology Unit) of the University of Newcastle (UoN)/Calvary Mater Newcastle Hospital (CMN) that consists of 3 postdoctoral researchers, 2 research assistants, 2 visiting academics, 6 PhD students, 1 laboratory manager, 1 technical officer, and 1 administrative officer.
He pioneered two areas of the the melanoma research field, overcoming resistance of melanoma cells to apoptosis induced by TRAIL (a soluble factor that can be produced by immune cells and selectively kill cancer cells without affecting normal tissues) and examining the response of melanoma cells to a cellular stress condition termed ER stress. While his leading role in these areas has been consolidated in recent years, he has initiated a number of new projects that advance the frontier of melanoma resaerch. These include projects to address the questions “what regulates sensitivity of melanoma cells to apoptosis induced by inhibition of intracellular pro-survival signalling pathways?”, “how do a group of proteins called polyphosphate phosphatase affect melanoma cell malignancy?”, “why does the tumour suppressor p53 not function to suppress melanoma?”, and “is there any relationship between obesity and melanoma development, progression, and resistance to treatment?”.
Professor Zhang’s research program is closely allied with the research scheme of the Melanoma Institute Australia (MIA). This not only allows my team to have full access to the largest repository of melanoma-related bio-samples with linked follow-up data in the world, but also fast tracks our scientific exchanges with melanoma researchers nationally and internationally. In addition, my research program is integrated into the research strategy of the Priority Research Center (PRC) for Cancer of UoN and that of the Cancer Research Program (CRP) of the Hunter Medical Research Institute (HMRI). This not only facilitates collaborations between his research team and other local cancer researchers, but also enables him to contribute his research expertise broadly to other cancer research programs in Newcastle.
Languages
- English
- Mandarin
Fields of Research
| Code | Description | Percentage |
|---|---|---|
| 111200 | Oncology And Carcinogenesis | 75 |
| 060199 | Biochemistry And Cell Biology Not Elsewhere Classified | 25 |
Memberships
Body relevant to professional practice.
- Member - American Association for Cancer Research (AACR)
- Member - the Analytical and Biomolecular Research Facility (ABRF) Advisory Group of University of Newcastle
Committee/Associations (relevant to research).
- Member - Executive Committee of Hunter Translational Cancer Research Unit (TCRU)
- Member - the Hunter Medical Research Institute (HMRI) Cancer Research Program (CRP) Steering Committee
- Member - the ERA 2012 Cluster Advisory Group of University of Newcastle
Editorial Board.
- Member - World Journal of Gastrointestinal Oncology
- Member - The Scientific World Journal
- Member - the Chinese Journal of Stem Cells
NHMRC Committee
- Member - Grant Review Panel
Appointments
| Senior Reserch Fellow NHMRC (Australia) | 01/01/2011 |
| Research Fellow Cancer Institute NSW (Australia) | 01/01/2011 |
| Research Fellow Cancer Institute NSW (Australia) | 01/01/2008 - 01/12/2010 |
| Resaerch Fellow Cancer Institute NSW (Australia) | 01/01/2006 - 01/12/2008 |
| Senior Brawn Research Fellow University of Newcastle (Australia) | 01/01/2011 |
Awards
Research Award.
| 2004 | Young Resaerch of the Year Hunter Medical Research Institute (Australia) To recognize my achievement in cancer research. |
|---|
Invitations
| Induction of apoptosis: the key for successful treatment of melanoma by mutant BRAF inhibitors? The BIT Science’ 4rd PEPCON Conference, China (Invited Presenter) | 2012 |
| Adaptation to ER stress as a driver of increased expression of Mcl-1 with melanoma progression. 7th Annual International Melanoma Congress, Australia (Invited Presenter) | 2010 |
| Up-regulation of Mcl-1 by the Unfolded Protein Response is Critical for Survival of Melanoma Cells upon ER stress. 7th World Congress on Melanoma, Austria (Invited Presenter) | 2009 |
| Up-regulation of Mcl-1 by the Unfolded Protein Response is Critical for Survival of Melanoma Cells upon ER stress. XXth IPCC & Vth IMRC, Japan (Invited Presenter) | 2008 |
Collaboration
Professor Zhang’s research excellence has enabled him to establish productive collaborations with other researchers, both within academia and commercial organizations. His research team has successfully completed contract work for the biocompanies, Peplin Biotechnology and Novogene Biotechnology on testing new drugs on melanoma cells. His collaborations with AstraZeneca, Roche, and GlaxoSmithKline (GSK) on testing novel targeted therapeutics are ongoing. His collaborations with Drs Rick Thorne, Nicole Verrills, Nicholas Bowden, Ming Yang, Professors Rodney Scott locally, Professors Richard Kefford and Richard Scolyer and Dr Helen Rizos at the University of Sydney, Drs Tao Liu and Belamy Cheung at the University of New South Wales, and Dr Jiezhong Chen at the University of Wollongong are also continuing.
Professor Zhang provides regular scientific consultancies not only locally and nationally, but also to cancer researchers of a number of universities and institutes in China. He has been an honorary professor of Anhui Medical University since 2003, and received another honorary professorship from the Fourth Military Medical University in 2010. He was honored with a third professorship in China by Shanxi Cancer Hospital/Shanxi Cancer Institute in 2012. He was also appointed as an honorary director of the Cellular and Molecular Biology Laboratory of the same hospital/institute.
Aside from the Chinese universites and institues where Professor Zhang is an honorary professor, He has also established collaborations with researchers from other universities in China, including the Sun Yat-sen University in Guangzhou (Professors Xiao Shi Zhang and Xiao Feng Zhu), the Sichuan University in Chengdu (Dr Yu Fang Wang), and the University of Science and Technology of China in Hefei (Professor Main Wu). All these universities are among top-20 universities in China according to 2011 ranking (the Sun Yat-sen University is ranked 10; the Sichuan University, 12; and the University of Science and Technology of China, 18). These collaborations have proven to be productive and mutually beneficial as demonstrated by collaborative publications and conference presentations.
Administrative
Administrative expertise
Dr Zhang acts as a team leader of a research group at the oncology and Immunology Unit that is specialized in research on melanoma biology
Teaching
Teaching expertise
Tumor biology; Tumor Immunology; Apoptosis; Signaling transduction.
Grants and Funding
Summary
| Number of grants | 34 |
|---|---|
| Total funding | $5,135,425 |
For project grants received where the lead institution is other than the University of Newcastle, details are shown in italics.
Click on a grant title below to expand the full details for that specific grant.
2013 (4 grants)
Functional consequences of epigenetic repression of PIB5PA in melanoma$359,250
Funding Body: Cancer Council NSW
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Dr Helen Rizos, Doctor Rick Thorne, Doctor Chen Chen Jiang | ||
| Scheme | Role | |
| Research Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $359,250 | 2013 | 2015 |
| GNo:G1200386 | ||
Targeting PP2A to improve the therapeutic efficacy of mutant BRAF inhibitors in melanoma$359,250
Funding Body: Cancer Council NSW
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Doctor Nikki Verrills, Doctor Chen Chen Jiang | ||
| Scheme | Role | |
| Research Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $359,250 | 2013 | 2015 |
| GNo:G1200388 | ||
Leica TP 1020 Automatic Tissue Processor for histology applications$35,000
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Doctor Pradeep Tanwar, Professor Eileen McLaughlin, Professor Xu Dong Zhang, Professor Robert Callister, Associate Professor Phillip Dickson, Professor Hubert Hondermarck, Doctor Jean-Marie Sontag, Professor Dirk Van Helden, Doctor Doug Smith, Doctor Phil Jobling, Associate Professor Estelle Sontag, Associate Professor Paul Tooney, Doctor Susan Hua, Doctor Janet Holt, Doctor Jay Horvat, Associate Professor Liz Milward, Professor Adam McCluskey, Associate Professor Brett Nixon, Doctor Rebecca Lim, Associate Professor Alan Brichta | ||
| Scheme | Role | |
| Equipment Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $35,000 | 2013 | 2013 |
| GNo:G1201185 | ||
Ultra-Low Temperature Cryogenic Freezer$24,596
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Doctor Jude Weidenhofer, Doctor Rick Thorne, Doctor Kathryn Skelding, Doctor Nikki Verrills, Doctor Pradeep Tanwar, Associate Professor Phillip Dickson, Doctor Murray Cairns, Professor Hubert Hondermarck, Professor Xu Dong Zhang, Associate Professor Estelle Sontag, Doctor Chen Chen Jiang, Associate Professor Liz Milward, Doctor Jean-Marie Sontag, Associate Professor Paul Tooney, Doctor Severine Roselli, Doctor Matt Dun, Doctor Chris Dayas, Doctor Lin Kooi Ong, Professor Dirk Van Helden, Mr Ben Copeland, Ms Gabrielle Briggs, Conjoint Professor Leonie Ashman, Professor John Rostas | ||
| Scheme | Role | |
| Equipment Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $24,596 | 2013 | 2013 |
| GNo:G1201189 | ||
2012 (5 grants)
Targeting Histone Deacetylases to Overcome Resistance of BRAFV600E Melanoma Cells to Apoptosis$346,974
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Conjoint Professor Peter Hersey, Dr Tao Liu, Doctor Chen Chen Jiang, Doctor Rick Thorne | ||
| Scheme | Role | |
| Project Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $346,974 | 2012 | 2014 |
| GNo:G1100133 | ||
The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$292,300
Funding Body: Cancer Institute NSW
| Project Team | ||
|---|---|---|
| Professor John Forbes, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Conjoint Associate Professor Barbara Young, Professor Hubert Hondermarck, Conjoint Professor Leonie Ashman, Professor Xu Dong Zhang, Doctor Kelly Kiejda, Doctor Nikki Verrills, Doctor Jennette Sakoff, Ms Janine Lombard, Doctor Jude Weidenhofer, Doctor Pradeep Tanwar | ||
| Scheme | Role | |
| Infrastructure Grants | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $292,300 | 2012 | 2014 |
| GNo:G1200798 | ||
High-Resolution Isoelectric Phosphoprotein Signalling System for Signalling Research, Biomarker Validation and Drug Development – Equipment Grant$143,394
Funding Body: Hunter Medical Research Institute
| Project Team | ||
|---|---|---|
| Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Lisa Lincz, Doctor Jennette Sakoff, Conjoint Professor Leonie Ashman | ||
| Scheme | Role | |
| Project Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $143,394 | 2012 | 2012 |
| GNo:G1200555 | ||
Microscopic illumination system for advanced fluorescent protein technology$34,000
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Doctor Rick Thorne, Professor Xu Dong Zhang, Doctor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Conjoint Professor Leonie Ashman, Professor Hubert Hondermarck | ||
| Scheme | Role | |
| Equipment Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $34,000 | 2012 | 2012 |
| GNo:G1100983 | ||
A p53-Mediated Pro-Survival Signaling Pathway in Human Melanoma Progression and Resistance to Treatment$20,000
Funding Body: University of Newcastle
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Doctor Rick Thorne, Doctor Chen Chen Jiang | ||
| Scheme | Role | |
| Near Miss Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $20,000 | 2012 | 2012 |
| GNo:G1200672 | ||
2011 (6 grants)
Overcoming resistance of human metastatic melanoma to treatment$570,640
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang | ||
| Scheme | Role | |
| Research Fellowships | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $570,640 | 2011 | 2015 |
| GNo:G1000048 | ||
Targeting pro-survival mechanisms to sensitize human melanoma to immunotherapy$359,250
Funding Body: Cancer Council NSW
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Doctor Ming Yang | ||
| Scheme | Role | |
| Research Program | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $359,250 | 2011 | 2013 |
| GNo:G1000379 | ||
Overcoming Resistance of Metastatic Melanoma to Treatment: 53 regulation of Mcl-1 via a microRNA-Mediated Pathway in Melanoma progression and Resistance to Chemotherapy$123,498
Funding Body: Cancer Institute NSW
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang | ||
| Scheme | Role | |
| Career Development Fellowship | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $123,498 | 2011 | 2014 |
| GNo:G1000815 | ||
Regulation of BimS splicing in response of human melanoma cells to inhibition of BRAFVV600E$25,000
Funding Body: Hunter Medical Research Institute
| Project Team | ||
|---|---|---|
| Doctor Chen Chen Jiang, Professor Xu Dong Zhang | ||
| Scheme | Role | |
| Project Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $25,000 | 2011 | 2011 |
| GNo:G1000988 | ||
Targeting Pro-Survival Mechanisms to Sensitize Human Melanoma to Immunotherapy$25,000
Funding Body: University of Newcastle
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Doctor Ming Yang | ||
| Scheme | Role | |
| Near Miss Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $25,000 | 2011 | 2011 |
| GNo:G1001046 | ||
The Role of Phosphatidylinositol 4, 5-Bisphosphate 5-Phosphatase A (PIB5PA) in Regulation of PI3K/Akt Signalling in Melanoma$24,000
Funding Body: Hunter Medical Research Institute
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Doctor Chen Chen Jiang | ||
| Scheme | Role | |
| Project Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $24,000 | 2011 | 2013 |
| GNo:G1101121 | ||
2010 (4 grants)
Transcriptional regulation of the expression of Mcl-1 in melanoma cell under ER stress$144,300
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Conjoint Professor Peter Hersey, Professor Xu Dong Zhang, Doctor Li Dong | ||
| Scheme | Role | |
| Training (Postdoctoral) Fellowships - Australia-China Exchange Fellowships | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $144,300 | 2010 | 2013 |
| GNo:G0190308 | ||
Melanoma Institute Australia Translational Research Program$58,405
Funding Body: Cancer Institute NSW
| Project Team | ||
|---|---|---|
| Professor Graham Mann, Professor John Thompson, Professor R Kefford, Clinical Professor Richard Scolyer, Professor Scott Menzies, Associate Professor Andrew Spillane, Conjoint Professor Peter Hersey, Dr Helen Rizos, Professor Xu Dong Zhang, Professor Richard Christopherson | ||
| Scheme | Role | |
| Translational Program Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $58,405 | 2010 | 2015 |
| GNo:G1200975 | ||
Targeting Pro-Survival Mechanisms to Sensitize Human Melanoma to Immunotherapy$48,200
Funding Body: Cancer Institute NSW
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang | ||
| Scheme | Role | |
| Research Innovation Grants | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $48,200 | 2010 | 2010 |
| GNo:G0190555 | ||
The role of micro-RNA-149 in Regulation of Mcl-1 in Human Melanoma under stress$20,000
Funding Body: Hunter Children`s Research Foundation
| Project Team | ||
|---|---|---|
| Doctor Chen Chen Jiang, Professor Xu Dong Zhang | ||
| Scheme | Role | |
| Research Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $20,000 | 2010 | 2010 |
| GNo:G0900189 | ||
2009 (4 grants)
Targeting adaptive mechanisms to endoplasmic reticulum stress in melanoma$491,250
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Conjoint Professor Peter Hersey, Doctor Rick Thorne | ||
| Scheme | Role | |
| Project Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $491,250 | 2009 | 2011 |
| GNo:G0188902 | ||
Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$272,000
Funding Body: Cancer Council NSW
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Conjoint Professor Peter Hersey, Doctor Kelly Kiejda | ||
| Scheme | Role | |
| Research Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $272,000 | 2009 | 2011 |
| GNo:G0188913 | ||
Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$75,000
Funding Body: Cancer Australia
| Project Team | ||
|---|---|---|
| Doctor Kelly Kiejda, Professor Xu Dong Zhang, Conjoint Professor Peter Hersey | ||
| Scheme | Role | |
| Priority-driven Collaborative Cancer Research | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $75,000 | 2009 | 2010 |
| GNo:G0188914 | ||
FACSAria$30,000
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Doctor Rick Thorne, Doctor Severine Roselli, Professor Xu Dong Zhang, Dr Charles De Bock, Conjoint Professor Peter Hersey, Professor Gordon Burns | ||
| Scheme | Role | |
| Equipment Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $30,000 | 2009 | 2009 |
| GNo:G0189846 | ||
2008 (1 grants)
Colibri high-performance LED illumination system for fluorescence live cell microscopy$23,225
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Doctor Rick Thorne, Dr Charles De Bock, Professor Xu Dong Zhang, Doctor Lisa Lincz, Professor Gordon Burns, Conjoint Professor Peter Hersey, Professor Dirk Van Helden, Conjoint Professor Keith Jones, Professor Roger Smith | ||
| Scheme | Role | |
| Equipment Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $23,225 | 2008 | 2008 |
| GNo:G0188545 | ||
2007 (4 grants)
Characterization of p53 isoforms in human melanoma: do they play a role in chemoresistance?$75,000
Funding Body: Cure Cancer Australia Foundation
| Scheme | Role | |
|---|---|---|
| Project Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $75,000 | 2007 | 2007 |
| GNo:18105190 | ||
The role of p53 Isoforms in chemoresistances of human melanoma$20,000
Funding Body: Hunter Medical Research Institute
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang, Doctor Kelly Kiejda | ||
| Scheme | Role | |
| Project Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $20,000 | 2007 | 2007 |
| GNo:G0187239 | ||
The role of p53 isoforms in chemoresistance of human melanoma. $0
Funding Body: Newcastle Mater Misericordiae Hospital
| Scheme | Role | |
|---|---|---|
| Small Grant | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $0 | 2007 | 2007 |
| GNo:18105231 | ||
molecular predictors of risk, progression and treatment response in melanoma$0
Funding Body: National Health & Medical Research Council
| Scheme | Role | |
|---|---|---|
| Program Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $0 | 2007 | 2007 |
| GNo:18105827 | ||
2006 (1 grants)
PRC - Priority Research Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine (CIBM)$621,143
Funding Body: University of Newcastle
| Project Team | ||
|---|---|---|
| Professor Pablo Moscato, Professor Rodney Scott, Professor John Rostas, Professor John Forbes, Conjoint Professor Peter Hersey, Conjoint Professor Stephen Ackland, Conjoint Professor Wayne Smith, Emeritus Professor Peter Dunkley, Conjoint Professor Leonie Ashman, Professor John Attia, Associate Professor Phillip Dickson, Associate Professor Liz Milward, Professor Alistair Sim, Associate Professor Paul Tooney, Associate Professor Regina Berretta, Conjoint Professor David Sibbritt, Conjoint Professor Chris Levi, Professor Xu Dong Zhang, Conjoint Associate Professor Patricia Crock, Conjoint Associate Professor Jeannette Lechner-Scott | ||
| Scheme | Role | |
| Priority Research Centre | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $621,143 | 2006 | 2013 |
| GNo:G0186919 | ||
2005 (4 grants)
Overcoming resistance of human melanoma to chemotherapy$492,750
Funding Body: NHMRC (National Health & Medical Research Council)
| Project Team | ||
|---|---|---|
| Conjoint Professor Peter Hersey, Professor Xu Dong Zhang, Dr John Allen | ||
| Scheme | Role | |
| Project Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $492,750 | 2005 | 2007 |
| GNo:G0183933 | ||
PULSE Young Medical Researcher of the Year Award$5,000
Funding Body: Hunter Medical Research Institute
| Project Team | ||
|---|---|---|
| Professor Xu Dong Zhang | ||
| Scheme | Role | |
| Young Medical Researcher of the Year Award | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $5,000 | 2005 | 2005 |
| GNo:G0184902 | ||
Overcoming Resistance of Melanoma to Chemotherapy$0
Funding Body: National Health & Medical Research Council
| Scheme | Role | |
|---|---|---|
| Project | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $0 | 2005 | 2007 |
| GNo:18105841 | ||
Overcoming Resistance of Melanoma to Chemotherapy: Are Melanoma Stem Cells Key Targets? $0
Funding Body: Cancer Institute NSW
| Scheme | Role | |
|---|---|---|
| Career Development and Support Fellowship | Chief Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $0 | 2005 | 2007 |
| GNo:18105807 | ||
2003 (1 grants)
Regulation of TNF Apoptosis Inducing Ligand (TRAIL) Receptor Expression in Human Melanoma Cells.$17,000
Funding Body: Hunter Medical Research Institute
| Project Team | ||
|---|---|---|
| Conjoint Professor Peter Hersey, Professor Xu Dong Zhang | ||
| Scheme | Role | |
| Research Grant | Investigator | |
| Total Amount | Funding Start | Funding Finish |
| $17,000 | 2003 | 2003 |
| GNo:G0182640 | ||
Research Supervision
| Number of current supervisions | 5 |
|---|---|
| Total current UoN PhD EFTSL | 2.45 |
For supervisions undertaken at an institution other that the University of Newcastle, details are shown in italics, and the institution name is listed below the program name.
Current Supervision
| Commenced | Proposed Completion | Program | Supervisor Type | Research Title |
|---|---|---|---|---|
| 2011 | 2015 | PhD (Surgical Science) | Principal Supervisor | Obesity in Melanoma Genesis, Progression and Resistance to Treatment |
| 2011 | 2015 | PhD (Surgical Science) | Principal Supervisor | Regulation of Apoptosis Induced by Targeting the RAF/MEK/ERK Pathway in Human Melanoma |
| 2010 | 2014 | PhD (Surgical Science) | Principal Supervisor | Targeting Adaptive Mechanism to ER Stress in Melanoma |
| 2008 | 2012 | PhD (Medical Biochemistry) | Co-Supervisor | The Role of MIF in Melanoma Progression |
| 2008 | 2012 | PhD (Surgical Science) | Co-Supervisor | Overcoming Resistance of Melanoma Cells to Apoptosis |
Past Supervision
| Year | Program | Supervisor Type | Research Title |
|---|---|---|---|
| 2012 | PhD (Surgical Science) | Co-Supervisor | Sensitising Human Melanoma Cells to TRAIL-induced Apoptosis |
| 2008 | PhD (Surgical Science) | Consultant Supervisor | Regulation of Endoplasmic Reticulum Stress Induced Apoptosis in Human Melanoma |
| 2007 | PhD (Surgical Science) | Co-Supervisor | Overcoming Resistance of Human Melanoma to Chemotherapy-Induced Apoptosis |
Professor Xu Dong Zhang
| Work Phone | (02) 4921 8906 |
|---|---|
| Cell / Mobile Phone | 0422621827 |
| Fax | (02) 4921 7311 |
| Xu.Zhang@newcastle.edu.au | |
| Position | Professor Melanoma Research Laboratory School of Biomedical Sciences and Pharmacy Faculty of Health and Medicine |
| Office | LS3-49, Life Sciences Building, Callaghan University Drive Callaghan NSW 2308 Australia |
| URL: | www.newcastle.edu.au/profile/xu-zhang |
News
Molecule may hold key to melanoma progression
The search for new pathways to treat melanoma has unearthed a molecular ta...
